Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07670416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

StatusRecruiting
PhasePhase 3
Started2026-07-03
View on ClinicalTrials.gov ↗

Amendment history

2026-09-08
Study Status, Contacts/Locations v3
Trial sites expanded: 18 → 21 locations
2026-08-12
Study Status, Contacts/Locations v2
Trial sites expanded: 12 → 18 locations
2026-07-13
Study Status, Contacts/Locations v1
Trial sites expanded: 3 → 12 locations
Primary completion date2028-03-12→2028-02-24
Completion date2028-04-02→2028-03-15
Start dateestimated 2026-06-25→confirmed 2026-07-03
2026-06-22
Original filing
Roche/Genentech
364 trials monitored
See 34 trials at risk
Diabetes
4,247 trials monitored
See 176 trials at risk
Obesity
3,523 trials monitored
See 133 trials at risk
Type 2 Diabetes
2,082 trials monitored
See 101 trials at risk
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.
Trial Details
NCT Number NCT07670416
Lead Sponsor Hoffmann-La Roche
Conditions Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Enrollment 300 participants
Start Date 2026-07-03
Primary Completion 2028-02-24 (estimated)
Study Completion 2028-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-10